AbbVie to Showcase Oncology Portfolio and Pipeline During th

AbbVie to Showcase Oncology Portfolio and Pipeline During the 2022 ASCO and EHA Annual Congresses

/PRNewswire/ -- AbbVie (NYSE: ABBV) will present 46 abstracts across eight types of cancer during the upcoming American Society of Clinical Oncology (ASCO)...

Related Keywords

Geest , Niedersachsen , Germany , United States , Ludwigshafen , Rheinland Pfalz , Argentina , American , Lemzoparlimab Lemzo , Epcoritamab Epco , Rituximab Ven , Venclyxto Sm , Osimertinib Osi , Telisotuzumab Vedotin Teliso , Mohamed Zaki , Telisotuzumab Vedotin , Navitoclax Monotherapy , Instagram , Abbvie Company , American Society Of Clinical Oncology , Janssen Biotech Inc , Genentech , Linkedin , Twitter , European Hematology Association , Us National Library Of Medicine , Allergan , Facebook , Abbvie Deutschland Gmbh Co , Translational Research , National Comprehensive Cancer Network , A Retrospective Analysis In Community , Drug Administration , Exchange Commission , Youtube , Development Of Novel Anti , Eupal International Collaboration , Roche Group , Diffuse Large Lymphoma Research Foundation , Macrophage Properties , American Society , Clinical Oncology , Annual Meeting , Results From , Combination With , Line Treatment , Older Patients , Mantle Cell Lymphoma , Hematologic Malignancies , Chronic Lymphocytic Leukemia , Small Lymphocytic Lymphoma , Follow Up From , Chronic Lymphocytic , Treatment Patterns , With Chronic , Proton Pump , During Routine , Clinical Outcomes , Patients Receiving Either Ibrutinib , Retrospective Analysis , World Clinical Outcomes , Either Ibrutinib , Combination With Azacitidine , Outpatient Setting , Myelodysplastic Syndromes , With High Risk Diffuse , Cell Lymphoma , Epcoritamab With Rituximab , With Relapsed , Diffuse Largeb Cell Lymphoma , Who Are Eligible , Cell Transplant , Stem Cell Transplant , High Response Rate Even , Plus Ruxolitinib , With Myelofibrosis , Open Label Phase , With Acute Myeloid Leukemia , Dose Escalation , Prior Osi , With Advanced , Met Overexpressing , Cell Lung Cancer , Lung Cancer , Advanced Non Small Cell Lung , Non Small Cell , Translational Analyses , First Line Treatment , Mantle Cell , Relapsing Chronic Lymphocytic , After First Line Treatment , Plus Venetoclax , Small Lymophocytic , Year Follow Up From , Trial Analysis , Fixed Duration Ibrutinib , Azacitidine Versus Oral , Patients With Acute , First Remission After , Patients With Acute Myeloid , Post Remission Granulocyte , Stimulating Factor Use , Venetoclax Combination Treatments , Patients With Newly Diagnosed Acute , Patients With , Hypomethylating Agents , Large Population Based , Patients With Chronic , Leukemia With , Genomic Analyses , With Targeted , Resource Utilization , Lymphocytic Lymphoma , Children With , Refractory Acute Myeloid , Versus Fludarabine , Chromic Lymphoma , Without Risk Associated , Risk Associated Genetic Markers , Life Efficacy , Interim Analysis , Combination With Obinutuzumab , First Line Chromic Leukemia , With Venetoclax , Myeloid Leukemia , With Anti Neoplastic Agents , With Non Hodgkin Lymphoma , Aggressive Non Hodgkin , Untreated Patients , Epcoritamab With , Update From Phase , Preliminary Phase , With Gemcitabine , Diffuse Largeb Cell , Who Are Ineligible , Preliminary Safety , Janssen Biotech , National Comprehensive Cancer , Patient Information , Medication Guide , Important Venclyxto , Crcl This , Allergan Aesthetics , Private Securities Litigation Reform Act , Quarterly Reports , Tyrosine Kinase , Product Characteristics , Abbvie Deutschland Gmbh , Largeb Cell Lymphoma , Research Foundation , Clinically Utilized , Directed Antibodies , Novel Anti Cd , Cell Surface , Cancer Sci Ther , Abbvie ,

© 2025 Vimarsana